Venture capital fund
Every published round Medical Research Commercialisation Fund (MRCF) took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
Companies Medical Research Commercialisation Fund (MRCF) has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| No portfolio companies recorded yet. | ||||
Fund closes reported for Medical Research Commercialisation Fund (MRCF), as distinct from the investments it has made.
Companies Medical Research Commercialisation Fund (MRCF) has backed that another company then bought. An exit for the holding, not a deal Medical Research Commercialisation Fund (MRCF) did.
Stories naming Medical Research Commercialisation Fund (MRCF). Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Uniseed-backed Australian medtech Q-Sera's blood-clotting tube technology has debuted in Japan via Terumo's VenoJect II launch; the post also credits MRCF and UniQuest Extension Fund as backers.
Q-Sera's rapid-clotting blood tube technology has gone to market in Japan via Terumo's VenoJect II launch; the Melbourne startup's backers include MRCF, Uniseed and the UniQuest Extension Fund.
Vaxxas has exclusively licensed UT Austin's HexaPro spike protein for a needle-free COVID-19 vaccine patch, backed by an NIH license, with a Phase 1 trial planned this year; background notes its founding backers.